On actionable guidance for community practitioners, Kamat's most emphatic recommendation is early pathology review. In this video, recorded at the 41st Annual Congress of the European Association of ...
The discussion explores how the rising burden of comorbidities and polypharmacy in patients with metastatic castration-sensitive prostate cancer requires clinicians to carefully balance therapy ...
Enzalutamide/leuprolide reduced metastasis or death versus leuprolide alone (HR 0.42) and improved overall survival (HR 0.597); enzalutamide monotherapy also improved ...
The discussion introduces how the treatment landscape for metastatic castration-sensitive prostate cancer has evolved, highlighting that patients are now living longer with metastatic disease and ...
The PRESERVE trial demonstrated a 71% negative in-field biopsy rate at 12 months, supporting the NanoKnife System's efficacy in prostate tissue ablation. Significant PSA level reductions and improved ...
Combining ¹⁷⁷Lu-rosopatamab tetraxetan with ARPIs or followed by docetaxel met primary safety/dosimetry objectives in a 36-patient international lead-in and supported feasibility within contemporary ...
Clearance of the non-permanent implant technology is backed by safety and efficacy results from the pivotal Expander-2 trial. On March 16, 2026, Prodeon Medical announced FDA 510(k) clearance for the ...
The NCCN now assigns a Category 2A recommendation for nadofaragene in patients with high-risk BCG-unresponsive NMIBC with papillary tumors without CIS. The OPTIMUM randomized trial demonstrated that ...
Telemedicine has also expanded access, allowing patients to choose either virtual or in-person visits. However, Kaylani Narra, MD, emphasized that limited genetic counseling capacity remains a major ...
Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...
A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...
Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results